We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

LumiraDx Presents its POC Diagnostics Platform and Broad Test Menu at MEDICA 2022

By HospiMedica International staff writers
Posted on 13 Oct 2022
Print article
Image: The innovative, next generation LumiraDx Point of Care Diagnostic Platform (Photo courtesy of LumiraDx)
Image: The innovative, next generation LumiraDx Point of Care Diagnostic Platform (Photo courtesy of LumiraDx)

LumiraDx (London, UK) is presenting its innovative, next generation POC diagnostics platform and broad test menu together with its Fast Lab Solutions at the 2022 edition of MEDICA, the world’s largest medical trade fair.

At MEDICA 2022, LumiraDx is presenting the LumiraDx Point of Care Diagnostic Platform, an innovative, next generation POC system that combines a small, portable instrument, advanced low cost test strip and seamless digital connectivity. Its proprietary technology enables it to deliver exceptional point of care clinical performance, while being simple and easy to use. The company is also showcasing the LumiraDx INR Test, an enzyme kinetic assay based on Thrombin activity. The coagulation cascade is activated by the test reagents and INR is calculated from the measured PT-time. Haematocrit is also measured on the strip to ensure patients are within the 25-55% range. The accuracy of the LumiraDx INR Test is comparable to the ACL Elite lab reference method. In addition, LumiraDx is highlighting the LumiraDx D-Dimer Test, a rapid microfluidic immunoassay for the quantitative determination of D-Dimer and the only D-Dimer Test to provide fast, accurate, quantitative results in just six minutes from a fingerstick blood sample.

Among its COVID-19 tests being highlighted at MEDICA 2022 is the LumiraDx SARS-CoV-2 Ag Test, a rapid microfluidic immunoassay for detecting SARS-CoV-2 antigen. The test uses nasal and nasopharyngeal swab samples to detect antigen nucleocapsid protein in under 12 minutes at POC. In clinical studies, the LumiraDx SARS-CoV-2 antigen test demonstrated 97.6% positive agreement versus RT-PCR in patients tested within 12 days of the onset of symptoms. The company is also showcasing LumiraDx SARS-CoV-2 Ab Test, a microfluidic immunofluorescence assay for the qualitative detection of total antibodies to SARS-CoV-2 in human whole blood (capillary fingerstick or venous), plasma or serum for indication of recent or prior infection. Used with the LumiraDx Platform, the test delivers rapid results at the POC.

Related Links:
LumiraDx 

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Silver Member
Wireless Mobile ECG Recorder
NR-1207-3/NR-1207-E
New
Ultrasound System
Voluson Signature 18

Print article

Channels

Critical Care

view channel
Image: The stretchable microneedle electrode arrays (Photo courtesy of Zhao Research Group)

Stretchable Microneedles to Help In Accurate Tracking of Abnormalities and Identifying Rapid Treatment

The field of personalized medicine is transforming rapidly, with advancements like wearable devices and home testing kits making it increasingly easy to monitor a wide range of health metrics, from heart... Read more

Patient Care

view channel
Image: The portable, handheld BeamClean technology inactivates pathogens on commonly touched surfaces in seconds (Photo courtesy of Freestyle Partners)

First-Of-Its-Kind Portable Germicidal Light Technology Disinfects High-Touch Clinical Surfaces in Seconds

Reducing healthcare-acquired infections (HAIs) remains a pressing issue within global healthcare systems. In the United States alone, 1.7 million patients contract HAIs annually, leading to approximately... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more